Background: Formerly, treating hepatitis C virus (HCV) infection in individuals suffering from chronic renal disease was challenging due to the toxicity of interferon (IFN). Ombitasvir, paritaprevir, and ritonavir are examples of safe and effective pan-genotypic direct-acting antiviral (DAA) regimens that make it easier for individuals with chronic kidney disease to treat their hepatitis C virus (HCV).
Objectives: To assess the effectiveness and safety of Omibtasvir, paritaprevir, and ritonavir when used in conjunction with Ribavirin for the treatment of hepatitis C patients who have end-stage kidney disease.
Patients and methods: 100 individuals with severe renal illnesses and chronic hepatitis C virus were included in this cross-sectional investigation. The estimated glomerular filtration rate (eGFR) was calculated after each patient underwent a thorough medical history, physical examination, and laboratory testing that included a complete blood count, ALT, AST, and kidney function tests. Fibroscan and pelvic abdominal ultrasonography were carried out. The patients received ribavirin together with paritaprevir/ritonavir and ombitasvir (75/50/12.5mg) twice day for 12 weeks.
Results: Sustained virologic response (SVR) was 83 % (83 patients) overall patients.  Patients were divided into two groups according to sustained virologic response. Child Pugh-turcotte (CPT) score was higher in non responders when compared with responders (5.7 ± 0.4 vs 5.4 ± 0.4; P-value = 0.002). Regarding to Safety and tolerability of DAAs, no severe adverse events were reported during the present study with no discontinuing treatment due to adverse events. The most frequent adverse events were anemia, headache, pruritus, anorexia and malaise.
Conclusion: OBV/PTV/RTV plus Ribavirin can be used in treatment of chronic HCV patients with ESRD with high virologic response and highly safety profile.